AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-TreatmentArm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401in Subjects With Preclinical Alzheimers Disease and Elevated Amyloid (A45 Trial)and in Subjects With Early Preclinical Alzheimers Disease and IntermediateAmyloid (A3 Trial)
||Male and Female Patients
|U.S. Govt. ID:
||Chrismary De La Cruz: 212-305-7661 / firstname.lastname@example.org
We are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks.
Karen Bell, MD
|Have you been diagnosed with Alzheimer's disease ?
|Are you between 55-80 years old?